Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Joseph

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
The Journal of Infectious Diseases|November 9, 2012
Defining falciparum-malaria-attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentrationIlse C E Hendriksen, Lisa J White, Jacobien Veenemans, et al.
Elife|October 6, 2020
The HIV-1 latent reservoir is largely sensitive to circulating T cellsJoanna A Warren, Shuntai Zhou, Yinyan Xu, et al.
Microorganisms|November 7, 2020
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African VolunteersFrank Msafiri, Agricola Joachim, Kathrin Held, et al.
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Journal of Virology|July 14, 2017
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine RegimenAsli Bauer, Lilli Podola, Philipp Mann, et al.
Biological Psychiatry|June 24, 2023
The Addition of Fish Oil to Cognitive Behavioral Case Management for Youth Depression: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialG Paul Amminger, Simon Rice, Christopher G Davey, et al.
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
The Journal of Infectious Diseases|November 9, 2012
Defining falciparum-malaria-attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentrationIlse C E Hendriksen, Lisa J White, Jacobien Veenemans, et al.
Elife|October 6, 2020
The HIV-1 latent reservoir is largely sensitive to circulating T cellsJoanna A Warren, Shuntai Zhou, Yinyan Xu, et al.
Microorganisms|November 7, 2020
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African VolunteersFrank Msafiri, Agricola Joachim, Kathrin Held, et al.
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Journal of Virology|July 14, 2017
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine RegimenAsli Bauer, Lilli Podola, Philipp Mann, et al.
Biological Psychiatry|June 24, 2023
The Addition of Fish Oil to Cognitive Behavioral Case Management for Youth Depression: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialG Paul Amminger, Simon Rice, Christopher G Davey, et al.
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Pageof 8